Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00447681 · ClinicalTrials.gov registry record · Phase 1

Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

A Phase 1 study of Healthy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
1
Study location

NCT00447681: Completed Phase 1 study of Healthy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

NCT00447681 is a Phase 1 study of Healthy that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 56 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00447681, a Phase 1 study of Healthy, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group study of ascending single IV doses of ILV-094, an investigational drug, administered to healthy subjects. In addition, there will be one sub-cutaneous dose cohort, which will follow the 25 mg IV dose.

Conditions Studied

Interventions

  • DRUG ILV-094

Study Locations (1)

Pennsylvania

  • - Philadelphia

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2006-12
Est. Completion 2007-11
Phase Phase 1

What the finished NCT00447681 record still lists

NCT00447681 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which ILV-094 is the first listed.

NCT00447681 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00447681 about?

NCT00447681 is a clinical study titled "Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects". This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group study of ascending single IV doses of ILV-094, an investigational drug, administered to healthy subjects. In addition, there will be one sub-cutaneous dose cohort, which will follow the 25 mg IV dose.

What is the current status of trial NCT00447681?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2006-12. Estimated completion is 2007-11.

What conditions does trial NCT00447681 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00447681?

The interventions under investigation include: ILV-094 (DRUG).

Who is sponsoring clinical trial NCT00447681?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00447681 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00447681's enrollment target sits among peer trials

56 413th of 1090 higher than 665 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00447681, the US trial registry maintained by the National Library of Medicine. NCT00447681 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.